NCT00729469 - Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity | Biotech Hunter

Enrollment

919

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

AtrophyVaginal Diseases

Interventions

DRUG

Ospemifene 60 mg

60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed

DRUG

Placebo

oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed